Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fast-tracking T cell therapies with immune-mimicking biomaterials

16.01.2018

A new approach to amplify patient-specific T cells outside the body could increase the efficiency of cancer immunotherapies

Immunologists and oncologists are harnessing the body's immune system to fight cancers and other diseases with adoptive cell transfer techniques. In a normal immune response, a type of white blood cell known as T cells are instructed by another kind of immune cell called an antigen-presenting cell (APC) to expand their numbers and stay alive. Adoptive cell transfer procedures are mimicking exactly this process in a culture dish by taking T cells from patients, multiplying them, sometimes genetically modifying them, and then returning them to patients so that they can, for example, locate and kill cancer cells. However, these procedures often take weeks to produce batches of therapeutic T cells that are large and reactive enough to be able to eliminate their target cells.


The left image shows a scanning electron micrograph (SEM) of a basic scaffold made of many tiny mesoporous silica rods (MSRs) before they are coated with a thin supported lipid bilayer (SLB) with the incorporated T cell-stimulating cues. In the right SEM image, T cells (in blue) bind to a section of a completed antigen-presenting cell-mimetic scaffold (in brown), where they are instructed to multiply and are kept alive for future use in T cell therapies.

Credit: Wyss Institute at Harvard University.

A team led by David Mooney at Harvard's Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) is now reporting in Nature Biotechnology an alternative material-based T-cell-expansion method that could help surmount these obstacles. With an APC-mimetic biomaterial scaffold, the researchers achieved greater expansion of primary mouse and human T cells than with existing methods; and they demonstrated the approach's potential in a mouse lymphoma model treated with chimeric antigen receptor-expressing T cells (CAR-T cells) that are engineered to home in on and destroy lymphoma cells.

"Our approach closely mimics how APCs present their stimulating cues to primary T cells on their outer membrane and how they release soluble factors that enhance the survival of the T cells. As a result, we achieve much faster and greater expansion. By varying the compositions of lipids, cues, and diffusible factors in the scaffolds, we engineered a very versatile and flexible platform that can be used to amplify specific T cell populations from blood samples, and that could be deployed in existing therapies such as CAR-T cell therapies," said Mooney, Ph.D., a Core Faculty member at the Wyss Institute and leader of its Immunomaterials Platform. Mooney is also the Robert P. Pinkas Family Professor of Bioengineering at SEAS.

... more about:
»T cells »Wyss »biomaterials »cell therapies »lymphoma

To engineer an APC-mimetic scaffold, the team first loaded tiny mesoporous silica rods (MSRs) with Interleukin 2 (IL-2) ¬-- an APC-produced factor that prolongs the survival of associated T cells. The MSRs were then coated with lipids that formed a thin supported lipid bilayer (SLB), which resembles the outer membrane of APCs and that the researchers then functionalized with a pair of T cell-stimulating antibodies that remain mobile in the lipid layer and can bind to receptor/co-receptor molecules on the surface of T cells. In culture medium, 3D scaffolds spontaneously formed through the settling and random stacking of the rods, forming pores big enough to allow the entry, movement, and accumulation of T cells, thereby signaling them to multiply.

In a series of side-by-side comparisons, Mooney's team demonstrated that APC-mimetic scaffolds performed better than methods involving commercially available expansion beads (Dynabeads), which are currently used in clinical adoptive cell transfer approaches. "In a single dose, APC-mimetic scaffolds led to two- to ten-fold greater expansion of primary mouse and human T cells than Dynabeads. As another advantage, APC-mimetic scaffolds enabled us to tune the ratios of subpopulations of T cells with different roles in the desired immune responses, which in the future might increase their functionality," said David Zhang, the study's second author and a Graduate Student working with Mooney.

Building on these findings, the researchers demonstrated the utility of their T cell expansion platform in a therapeutic model. "Prompted by recent breakthroughs in CAR-T cell therapies, we showed that a specific CAR-T cell product expanded with an APC-mimetic scaffold could facilitate treatment of a mouse model of a human lymphoma cancer," said first author Alexander Cheung, Ph.D., who started the project in Mooney's team and now is a scientist at UNUM Therapeutics in Cambridge, Massachusetts. An APC-mimetic scaffold that was engineered to activate a specific type of CAR-T cell was able to generate higher numbers of the modified T cells over longer periods of culture than analogously designed expansion beads, and the resulting cells were similarly effective in killing the lymphoma cells in the mice.

After successfully using the material to expand all T cells present in a sample, the team demonstrated that APC-mimetic scaffolds could also be used to expand antigen-specific T cell clones from a more complex mixture of cells. Such T cell clones are constantly developed by the immune system to recognize small specific peptides contained in foreign proteins. To this aim, the researchers incorporated molecules into the scaffolds that are known as the major histocompatibility complex (MHC) and that presented small peptides derived from viral proteins to T cells.

"Based also on studies in which we showed that APC-mimetic scaffolds also have superior potential to specifically enrich and expand rare T cell sub-populations from blood, we strongly believe that we created an effective platform technology that could facilitate more effective precision immunotherapies," said Cheung.

"The bioinspired T cell-activating scaffolds developed by the Wyss Institute's Immunomaterials Platform could accelerate the success of many immunotherapeutic approaches in the clinic, with life-saving impact on a broad range of patients, in addition to advancing personalized medicine," said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at SEAS.

###

In addition, Sandeep Koshy, Ph.D., who worked as a Graduate Student on Mooney's team and now is an Immuno-oncology Researcher at the Novartis Institutes for BioMedical Research in Cambridge, Mass., is an author on the study. The work was supported by the Wyss Institute for Biologically Inspired Engineering at Harvard University, the National Institutes of Health, and the National Science Foundation.

MULTIMEDIA AVAILABLE

PRESS CONTACT

Wyss Institute for Biologically Inspired Engineering at Harvard University Benjamin Boettner
617-432-8232
benjamin.boettner@wyss.harvard.edu

MULTIMEDIA CONTACT

Wyss Institute for Biologically Inspired Engineering at Harvard University Seth Kroll
617-432-7758
seth.kroll@wyss.harvard.edu

The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard's Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité - Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.

The Harvard John A. Paulson School of Engineering and Applied Sciences serves as the connector and integrator of Harvard's teaching and research efforts in engineering, applied sciences, and technology. Through collaboration with researchers from all parts of Harvard, other universities, and corporate and foundational partners, we bring discovery and innovation directly to bear on improving human life and society.

Media Contact

Benjamin Boettner
Benjamin.Boettner@wyss.harvard.edu
917-913-8051

 @wyssinstitute

http://wyss.harvard.edu/ 

 

Benjamin Boettner | EurekAlert!

Further reports about: T cells Wyss biomaterials cell therapies lymphoma

More articles from Health and Medicine:

nachricht Research offers clues for improved influenza vaccine design
09.04.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Injecting gene cocktail into mouse pancreas leads to humanlike tumors
06.04.2018 | University of Texas Health Science Center at San Antonio

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

Im Focus: The Future of Ultrafast Solid-State Physics

In an article that appears in the journal “Review of Modern Physics”, researchers at the Laboratory for Attosecond Physics (LAP) assess the current state of the field of ultrafast physics and consider its implications for future technologies.

Physicists can now control light in both time and space with hitherto unimagined precision. This is particularly true for the ability to generate ultrashort...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Diamond-like carbon is formed differently to what was believed -- machine learning enables development of new model

19.04.2018 | Materials Sciences

Electromagnetic wizardry: Wireless power transfer enhanced by backward signal

19.04.2018 | Physics and Astronomy

Ultrafast electron oscillation and dephasing monitored by attosecond light source

19.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>